Core Insights - GSK plc announced the European Commission's approval of its respiratory drug Nucala (mepolizumab) for treating certain patients with chronic obstructive pulmonary disease (COPD), marking a new indication for the drug [1] Group 1: Drug Approval and Indications - Nucala is now approved as an add-on maintenance treatment for uncontrolled COPD in adults with a raised blood eosinophil count, in combination with an inhaled corticosteroid, a long-acting beta2-agonist, and a long-acting muscarinic antagonist in the European Union [2] - The approval was anticipated following a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in December 2025 [2] - Nucala is the first and only monthly biologic in the EU studied in a broad group of COPD patients with an eosinophilic phenotype [3][7] Group 2: Clinical Data and Efficacy - The approval for Nucala in the EU was based on positive data from the phase III MATINEE study, which showed a clinically meaningful and statistically significant reduction in the annualized rate of moderate/severe exacerbations compared to placebo plus standard of care [8] - Data from the MATINEE study also indicated that Nucala treatment led to a reduction in exacerbations resulting in emergency department visits and/or hospitalizations [9] - Exacerbations are acute episodes of worsening COPD symptoms that can lead to hospitalization and irreversible lung damage, making their prevention a key goal in managing COPD [9] Group 3: Market Impact and Financial Performance - COPD affects over 390 million people globally, including about 40 million in Europe, and is one of the leading causes of hospitalization worldwide [10] - Nucala is a monoclonal antibody targeting IL-5, a key messenger protein in type 2 inflammation, and is also approved for four other IL-5-mediated conditions [11] - Nucala generated sales of £2.01 billion in 2025, reflecting a 15% year-over-year increase at constant exchange rates, and remains a key top-line driver for GSK [11] Group 4: Stock Performance - Over the past six months, GSK's shares have surged by 57.5%, outperforming the industry's rally of 43.5% [4]

Core Viewpoint - GSK's Nucala has received FDA approval for a fifth indication, allowing it to treat certain patients with chronic obstructive pulmonary disease (COPD), marking a significant expansion of its therapeutic applications [1][3]. Group 1: Product Approval and Indications - Nucala is now approved as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype [1]. - The drug is already approved for severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome in various regions, including the U.S. and Europe [2]. - The approval was supported by data from the late-stage MATINEE study, which demonstrated a significant reduction in the annualized rate of moderate to severe exacerbations when Nucala was added to inhaled maintenance therapy [3]. Group 2: Market Context and Competition - The FDA's decision makes Nucala the second biologic treatment approved for COPD and the third new COPD drug approved in the U.S. in the past year [9]. - Nucala will compete directly with Sanofi and Regeneron's Dupixent, which was the first biologic treatment for COPD approved in September of the previous year [10]. - Verona Pharma's Ohtuvayre was also approved last year as the first inhaled product with a novel mechanism of action for COPD maintenance treatment in over 20 years, highlighting the competitive landscape [11]. Group 3: Company Strategy and Financial Outlook - GSK aims to generate over £40 billion in annual sales by 2031, focusing on therapeutic areas such as HIV, immunology/respiratory, and oncology [5]. - The company expects to launch five new products or line extensions this year, with three already approved in the first half of 2025 [6]. - Year-to-date, GSK shares have gained 15%, outperforming the industry, which has seen a 6% decline [7].